Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3686045 | 0.84 | TDP1 (0.46) | TDP1TP53CYP1A2CYP2A6ALDH1A1 | |
| SCHEMBL7333612 | 0.80 | ALDH1A1 (0.42) | TDP1TP53CYP1A2CYP2A6ALDH1A1 | |
| SCHEMBL30150790 | 0.75 | TDP1 (0.42) | TDP1TP53CYP1A2CYP2A6ALDH1A1 | |
| SCHEMBL30361887 | 0.75 | TSHR (0.52) | TDP1TP53CYP1A2CYP2A6ALDH1A1 | |
| SCHEMBL1610965 | 0.75 | TDP1 (0.42) | TDP1TP53CYP1A2CYP2A6ALDH1A1 | |
| SCHEMBL277588 | 0.75 | TSHR (0.52) | TDP1TP53CYP1A2CYP2A6ALDH1A1 | |
| SCHEMBL1611111 | 0.75 | TDP1 (0.42) | TDP1TP53CYP1A2CYP2A6ALDH1A1 | |
| SCHEMBL935347 | 0.75 | TDP1 (0.42) | TDP1TP53CYP1A2CYP2A6ALDH1A1 | |
| SCHEMBL98000 | 0.75 | TDP1 (0.42) | TDP1TP53CYP1A2CYP2A6ALDH1A1 | |
| SCHEMBL19604062 | 0.73 | TDP1 (0.41) | TDP1TP53CYP1A2CYP2A6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2567964-B1 | Monomer compositions for the synthesis of RNA, methods of synthesis, and methods of deprotection | AGILENT TECHNOLOGIES INC (US) | 2015-02-11 | — | — | EP | claimed |
| EP-2567964-A2 | Monomer Compositions for the Synthesis of RNA, Methods of Synthesis, and Methods of Deprotection | Agilent Technologies, Inc. (US) | 2013-03-13 | — | — | EP | claimed |
| US-7759471-B2 | nucleotide monomer used to make protected RNA that has similar stability to the DNA molecule | AGILENT TECHNOLOGIES, INC. (US) | 2010-07-20 | — | — | US | claimed |
| US-20070100138-A1 | Monomer compositions for the synthesis of polynucleotides, methods of synthesis, and methods of deprotection | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2007-05-03 | — | — | US | claimed |
| US-20070100136-A1 | Monomer compositions for the synthesis of RNA, methods of synthesis, and methods of deprotection | AGILENT TECHNOLOGIES, INC. | 2007-05-03 | — | — | US | claimed |
| EP-2567964-B1 | Monomer compositions for the synthesis of RNA, methods of synthesis, and methods of deprotection | AGILENT TECHNOLOGIES INC (US) | 2015-02-11 | — | — | EP | disclosed |
| CN-102300925-B | Curable composition | CEMEDINE CO LTD | 2014-06-18 | — | — | CN | disclosed |
| US-8552174-B2 | Solutions, methods, and processes for deprotection of polynucleotides | AGILENT TECHNOLOGIES, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| EP-2567964-A2 | Monomer Compositions for the Synthesis of RNA, Methods of Synthesis, and Methods of Deprotection | Agilent Technologies, Inc. (US) | 2013-03-13 | — | — | EP | disclosed |
| US-8202985-B2 | Monomer compositions for the synthesis of polynucleotides, methods of synthesis, and methods of deprotection | AGILENT TECHNOLOGIES, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-7759471-B2 | nucleotide monomer used to make protected RNA that has similar stability to the DNA molecule | AGILENT TECHNOLOGIES, INC. (US) | 2010-07-20 | — | — | US | disclosed |
| EP-1792909-A1 | Synthesis of polynucleotides | Agilent Technologies, Inc. (US) | 2007-06-06 | — | — | EP | disclosed |
| US-20070100138-A1 | Monomer compositions for the synthesis of polynucleotides, methods of synthesis, and methods of deprotection | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2007-05-03 | — | — | US | disclosed |
| US-20070100136-A1 | Monomer compositions for the synthesis of RNA, methods of synthesis, and methods of deprotection | AGILENT TECHNOLOGIES, INC. | 2007-05-03 | — | — | US | disclosed |
| US-20070100137-A1 | Solutions, methods, and processes for deprotection of polynucleotides | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070100136-A1 | Monomer compositions for the synthesis of RNA, methods of synthesis, and methods of deprotection | RNGTT, RNMT, NSUN2 | TDP1 497/4885TP53 2653/4885CYP1A2 4597/4885 |
| US-20070100138-A1 | Monomer compositions for the synthesis of polynucleotides, methods of synthesis, and methods of deprotection | POLN, NT5C3B, PCNA | TDP1 192/4885TP53 2326/4885CYP1A2 4744/4885 |
| US-20070100137-A1 | Solutions, methods, and processes for deprotection of polynucleotides | POLN, POLRMT, POLM | TDP1 81/4885TP53 984/4885CYP1A2 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.